Established in 2013, Polpharma Biologics is the biotechnology unit of the rapidly growing ­Polpharma Group – one of the largest pharmaceutical players in the CEE region. Currently, with over 140 people, four sites, and full expertise for biopharmaceutical development and production, Polpharma Bio­logics is running five projects dedicated to monoclonal antibodies, and is just stepping into the contract development and manufacturing business.

Small companies and academic institutions develop their assets, in most cases, under budget constraints. Still, they have to meet the expectations of future strategic partners or investors in order to be an attractive option for them and to have a chance to get the pro­duct onto the market.

In December 2016, US biotech company Ionis Pharmaceuticals’ drug Spinraza received regulatory approval in the US. No doubt: the antisense technology behind Spinraza could be the next big thing

The decision of the European Patent Office to examine all patent applications within 12 months can unintentionally block companies from filing for life sciences patents in Europe, says Gavin Recchia, Principal of one of Australia’s largest patent attorneys’ firms.

There’s no way around it: renewables are the future, Matti Heikkilä believes. European Biotechnology talked to the CTO of Finnish bioeconomy company MetGen about what bio-based products need to bring to the table to usurp their fossil-based counterparts. 

The pharmaceutical industry of the European Union is currently toiling at a veritably Herculean task. They jointly took up the fight against falsified pharmaceuticals in the legal supply chain. Forgers have discovered that falsified drugs are a lucrative business. However, the EU legislature has recognised this risk, and responded by passing the Falsified Medicines Directive in 2011. In 2016, it was put in more concrete terms with the delegated regulation, which stipulates the implementation of the directive for prescription drugs.

Like every sector of the UK economy, life sciences has been beset with uncertainty since the country voted to leave the European Union. Last week prime minister Theresa May finally gave us some clarity on her plans for Brexit, which will allow us to prepare for the future.

The surprising election of Donald Trump as the next US President led to a spectacular comeback of biotech shares. The long-term prospects depend on Trump’s healthcare strategy and the (much-desired) return of generalist funds.

The randomised clinical trial (RCT) is the gold standard for drug evaluation. RCTs provide the core for drug development and subsequent drug approval – often in the form of rigorously designed efficacy trials in carefully selected subjects. In fact, in- and exclusion criteria are often so restrictive that only 1–7% of patients from outpatient clinics would be eligible for trials in asthma and chronic obstructive pulmonary disease (COPD).

Well, that was a weight off my chest, better out than in, as they say. After Brexit, at least the world will be pulled back into its axis with the election of America’s first woman president and … wait a minute, what are you saying? No, that can’t be right … he won? Really? REALLY?